from the article the deal made it possible for his company to inflate, by more than 50 percent, the number of test orders it reported to investors late

from the article the deal made it possible for his company to inflate, by more than 50 percent, the number of test orders it reported to investors late last year while updating them on interest in a flagship product, a diagnostic tool known as GPS Cancer. Have individual investors been questioned? No. But that's a significant increase in total orders. Also, if this was so above-board, want to take bets on whether this was disclosed to investors as money coming from related entities?